



## **Ventripoint Hires MarketSmart Communications to Provide Investor Relations Services**

**Toronto, Ontario – The Newswire – February 5, 2021** - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) announces it has entered into an investor relations agreement with MarketSmart Communications Inc. pursuant to which MarketSmart will provide investor relations (IR) services to Ventripoint. The IR agreement is for an initial term of six months commencing on February 5<sup>th</sup>, 2021, with an option for renewal. Either party may terminate the agreement for any reason, with or without cause, on 15-days written notice to the other.

"We are looking forward to working with MarketSmart to inform shareholders and new investors about the Company's progress to improve cardiac care worldwide," stated Dr. George Adams, Executive-Chairman of Ventripoint. "By expanding our outreach program, we hope to add to our loyal supporters and better reflect the true value of the Company."

Adrian Sydenham, President and a Director of MarketSmart Communications, stated: "Ventripoint's innovative, proprietary four-chamber cardiac analysis technology provides the medical community with a more efficient and effective analysis for the whole heart, unlike current methods. Its VMS+3.0 product has market authorizations in Canada, the USA, and the EU and is installed in the first eleven top hospitals. There is an exponential growing demand for this technology as many Covid-19 patients are experiencing long term adverse health implications of the heart. A fresh injection of funds through warrant exercise has Ventripoint well positioned to execute its corporate objectives. MarketSmart is delighted to have been awarded the investor relations contract, and we look forward to creating additional awareness in the investment community."

Pursuant to the IR agreement, MarketSmart will be paid a fee of \$9,500 per month, plus applicable taxes, and will be granted stock options to purchase 400,000 common shares of Ventripoint at a price of \$0.25 per share for a term of two years in accordance with the Ventripoint's stock option plan and vesting quarterly over 1 year. The IR agreement and grant of the options are subject to the approval of the TSX Venture Exchange.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of

Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

MarketSmart Communications Inc.  
1-877-261-4466  
Info@marketsmart.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

### **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.